1)日本皮膚科学会円形脱毛症ガイドライン作成委員会:日本皮膚科学会円形脱毛症診療ガイドライン2017年版.日皮会誌127:2741-2762, 2017
2)Campos-Alberto E, et al:Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata;A descriptive study using Japan medical data center claims database. J Dermatol 50:37-45, 2023
3)Olsen EA, et al:Alopecia areata investigational assessment guidelines;Part II. J Am Acad Dermatol 51:440-447, 2004
4)Fukuyama M, et al:Alopecia areata;Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 49:19-36, 2022
5)King B, et al:Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 386:1687-1699, 2022
6)Kwon O, et al:Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase Ⅲ trials(BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol 24:443-451, 2023
7)日本皮膚科学会脱毛症治療安全性検討委員会:安全使用マニュアル バリシチニブ—円形脱毛症(販売名:オルミエント錠2 mg,オルミエント錠4 mg).日皮会誌132:1813-1822, 2022